Neurology · Hereditary Transthyretin Amyloidosis

Your Care Team and Long-Term Monitoring

At a Glance

Hereditary ATTR amyloidosis needs coordinated, ongoing monitoring because it can affect nerves, the heart, automatic body functions, digestion, eyes, and kidneys. A personalized team checks for hidden changes, responds to warning signs, and guides genetic testing for relatives.

Because hATTR can affect nearly every system in your body, your care cannot be managed by a single doctor. Success in managing this condition requires a multidisciplinary care team—a group of specialists who coordinate their efforts to protect your organs and maintain your quality of life ^[1]. Ideally, this care should be centered at a specialized amyloidosis center where the team is familiar with the unique “tricks” of the TTR protein ^[2].

Building Your Care Team

Your team is often anchored by a Neurologist (to manage nerve health) and a Cardiologist (to monitor the heart) ^[3]. However, a complete team also includes:

Medical Geneticist/Genetic Counselor: To help you and your family navigate the implications of the TTR mutation ^[4].
Autonomic Specialist: A neurologist who focuses on “automatic” functions like blood pressure and digestion ^[5].
Gastroenterologist & Nutritionist: To manage symptoms like chronic diarrhea or unintended weight loss ^[6].
Ophthalmologist: To monitor for amyloid deposits in the eyes, which can occur even if your heart and nerves are stable ^[7].
Nephrologist: To monitor kidney health, especially if you are taking medications that can affect the kidneys ^[8].

Individualized Active Surveillance

Even if you feel well, hATTR requires “active surveillance.” Because symptoms can be subclinical (happening without you noticing), your team will monitor your condition. The schedule is individualized; while evaluations often happen every 6 to 12 months, the frequency depends on phenotype, symptoms, and therapy ^[3]^[9]. These evaluations often include:

Neurological: Physical exams and nerve conduction studies. Skin biopsies (small-fiber assessments) are selective and not required at every visit ^[10]^[11].
Cardiac: Blood tests for NT-proBNP and Troponin, an ECG to check for rhythm issues, and an echocardiogram ^[12]^[13].
Autonomic: “Orthostatic vitals” (checking your blood pressure and heart rate while lying down versus standing) and questionnaires like the COMPASS-31 ^[14]^[15].
Nutritional: Tracking your modified BMI (weight adjusted by your protein/albumin levels) ^[16]^[6].

Recognizing Medical Emergencies

While most hATTR symptoms progress slowly, certain “red flags” require immediate medical attention. Do not wait for your scheduled appointment if you experience:

Stroke Warning Signs: Sudden weakness on one side of the body, or sudden changes in speech or vision, should be treated first as a possible stroke. Call emergency services immediately even if symptoms resolve, rather than assuming it is hATTR progression ^[17]^[18].
Cardiac Crisis: Acute cardiac deterioration can occur. Severe chest pain, fainting (syncope), severe shortness of breath, or rapidly worsening swelling require urgent care ^[19]^[20].
Medication Emergencies: If taking inotersen, new petechiae (red spots on skin) or unusual bleeding, as well as reduced/foamy urine, require immediate reporting. Severe infusion or allergic symptoms can also occur with infusional therapies.

Cascade Testing: Protecting Your Family

Because hATTR is an autosomal dominant condition, your diagnosis provides an early warning for your blood relatives. Cascade testing is the process of offering genetic testing to your siblings and children ^[4].

Genetic Counseling First: Family members should speak with a genetic counselor before being tested to understand the psychological, reproductive, and practical impact of the results ^[21]. Predictive testing of a minor child with an usually adult-onset condition is typically deferred until they can make their own informed decision.
Asymptomatic Carriers: If a family member has the mutation but no symptoms, they are not “sick” and are not automatically started on disease-modifying therapy. Instead, they should begin baseline surveillance at an age individualized by a genetic counselor and amyloidosis specialist. This ensures that if the protein ever starts to misfold, they can be monitored and treated appropriately ^[21]^[9]^[22].

Common questions in this guide

Why do people with hereditary ATTR amyloidosis need several specialists?

Hereditary ATTR amyloidosis can affect the nerves, heart, automatic body functions, digestion, eyes, and kidneys. A neurologist and cardiologist often coordinate care, while genetics, nutrition, eye, kidney, and other specialists are added according to each person’s needs.

How often should hereditary ATTR amyloidosis be monitored?

Many people have evaluations every 6 to 12 months, but the schedule is individualized. Your care team may adjust it based on your disease pattern, symptoms, and treatment, even when you feel well.

What tests are used to monitor hATTR amyloidosis?

Monitoring may include neurological examinations and nerve studies, heart blood tests, an electrocardiogram, and an echocardiogram. Teams may also check blood pressure and heart rate when changing position, use symptom questionnaires, and track weight and protein levels; skin biopsies are used selectively.

Which hATTR symptoms require emergency medical care?

Call emergency services for sudden weakness on one side, new speech or vision changes, severe chest pain, fainting, severe shortness of breath, or rapidly worsening swelling. If you take inotersen, unusual bleeding, red spots on the skin, or reduced or foamy urine should be reported immediately, and severe allergic or infusion symptoms need urgent attention.

Should my children and siblings have genetic testing for hATTR?

Because hATTR can be passed through families, adult blood relatives may be offered cascade genetic testing. Genetic counseling should come first, and testing for a minor is often deferred for an adult-onset condition; relatives who carry the mutation usually need individualized surveillance rather than automatic treatment.

Curated prompts to bring to your next appointment.

1.Who is the 'lead coordinator' for my care team to ensure all my specialists are communicating?
2.Based on my specific mutation and current symptoms, which organ systems need the most frequent monitoring?
3.Are there specific specialists, like an autonomic neurologist or a specialized nutritionist, that I haven't seen yet but should?
4.If I experience a dizzy spell or fainting, how should I determine if it's an emergency or a symptom we can manage at home?
5.How can we best coordinate genetic counseling and 'baseline' screening for my children and siblings?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

A neurologist and cardiologist often anchor a multidisciplinary hATTR care team, with genetics, autonomic, digestive and nutrition, eye, and kidney specialists added as needed.
Active surveillance is often scheduled every 6 to 12 months, but testing frequency depends on the person’s symptoms, disease pattern, and therapy.
Monitoring may include nerve exams, heart blood tests and imaging, standing-versus-lying blood pressure checks, and nutrition tracking.
Sudden weakness or speech or vision changes, severe chest pain, fainting, severe shortness of breath, or rapidly worsening swelling require urgent medical attention.
Genetic counseling should come before cascade testing, and asymptomatic relatives with a TTR mutation generally need individualized surveillance rather than automatic treatment.

References (22)

1
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.
Adams D, Algalarrondo V, Polydefkis M, et al.
Orphanet journal of rare diseases 2021; (16(1)):411 doi:10.1186/s13023-021-01960-9.
PMID: 34602081
2
[Neurological manifestations of ATTR amyloidosis].
Pernice HF, Hahn K
Innere Medizin (Heidelberg, Germany) 2023; (64(9)):848-854 doi:10.1007/s00108-023-01570-6.
PMID: 37555967
3
Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal.
Ando Y, Waddington-Cruz M, Sekijima Y, et al.
Orphanet journal of rare diseases 2023; (18(1)):323 doi:10.1186/s13023-023-02910-3.
PMID: 37828588
4
Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.
Gillmore JD, Reilly MM, Coats CJ, et al.
Advances in therapy 2022; (39(6)):2292-2301 doi:10.1007/s12325-022-02139-9.
PMID: 35419651
5
Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
Gonzalez-Duarte A
Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(2)):245-251 doi:10.1007/s10286-018-0514-2.
PMID: 29511897
6
Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis.
Obici L, Suhr OB
Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(Suppl 1)):55-63 doi:10.1007/s10286-019-00628-6.
PMID: 31452022
7
OPHTHALMOLOGIC INVOLVEMENT IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS.
Ruiz-Medrano J, Puertas M, Almazán-Alonso E, et al.
Retina (Philadelphia, Pa.) 2023; (43(1)):49-56 doi:10.1097/IAE.0000000000003641.
PMID: 36228151
8
Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.
Meléndrez-Balcázar E, Aranda-Vela K, Cervantes-Hernández A, López-Cureño S
American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (84(2)):224-231 doi:10.1053/j.ajkd.2024.01.527.
PMID: 38484868
9
Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations.
Conceição I, Damy T, Romero M, et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2019; (26(1)):3-9 doi:10.1080/13506129.2018.1556156.
PMID: 30793974
10
Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.
Dyck PJB, González-Duarte A, Obici L, et al.
Journal of the neurological sciences 2019; (405()):116424 doi:10.1016/j.jns.2019.116424.
PMID: 31445300
11
Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.
Beauvais D, Labeyrie C, Cauquil C, et al.
Journal of neurology, neurosurgery, and psychiatry 2024; (95(6)):489-499 doi:10.1136/jnnp-2023-332180.
PMID: 37875336
12
Amyloid cardiomyopathy.
Kristen AV
Herz 2020; (45(3)):267-271 doi:10.1007/s00059-020-04904-4.
PMID: 32107564
13
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD, Adams D, Kristen A, et al.
Circulation 2019; (139(4)):431-443 doi:10.1161/CIRCULATIONAHA.118.035831.
PMID: 30586695
14
Evaluation of autonomic dysfunction in hereditary transthyretin amyloidosis.
Martínez-Valle F, Casasnovas-Pons C, Romero-Acebal M, Galán-Dávila L
Neurologia 2025; (40(9)):915-923 doi:10.1016/j.nrleng.2025.08.002.
PMID: 41198384
15
Role of ambulatory blood pressure monitoring as a non-invasive autonomic screening tool in hereditary transthyretin amyloidosis.
Sander L, Chiaro G, Abelardo D, et al.
Journal of neurology, neurosurgery, and psychiatry 2026; (97(3)):274-277 doi:10.1136/jnnp-2025-337061.
PMID: 41390239
16
Outcome of gastric emptying and gastrointestinal symptoms after liver transplantation for hereditary transthyretin amyloidosis.
Wixner J, Sundström T, Karling P, et al.
BMC gastroenterology 2015; (15()):51 doi:10.1186/s12876-015-0284-4.
PMID: 25908211
17
CNS Involvement in Hereditary Transthyretin Amyloidosis.
Sousa L, Coelho T, Taipa R
Neurology 2021; (97(24)):1111-1119 doi:10.1212/WNL.0000000000012965.
PMID: 34663645
18
Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis.
Sekijima Y, Yazaki M, Oguchi K, et al.
Neurology 2016; (87(8)):773-81 doi:10.1212/WNL.0000000000003001.
PMID: 27466465
19
Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.
Nativi-Nicolau JN, Karam C, Khella S, Maurer MS
Heart failure reviews 2022; (27(3)):785-793 doi:10.1007/s10741-021-10080-2.
PMID: 33609196
20
Predictors of poor prognosis in a large cohort of patients with hereditary cardiac transthyretin amyloidosis.
Ripoll-Vera T, de Frutos F, González-Costello J, et al.
Revista espanola de cardiologia (English ed.) 2026; (79(7)):618-630 doi:10.1016/j.rec.2025.12.016.
PMID: 41448563
21
Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies.
Ueda M, Sekijima Y, Koike H, et al.
Journal of the neurological sciences 2020; (414()):116813 doi:10.1016/j.jns.2020.116813.
PMID: 32353608
22
Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature.
Dohrn MF, Auer-Grumbach M, Baron R, et al.
Journal of neurology 2021; (268(10)):3610-3625 doi:10.1007/s00415-020-09962-6.
PMID: 32500375

This page is for informational purposes only and does not constitute medical advice. Your amyloidosis team should tailor monitoring, emergency guidance, and family genetic counseling to your situation.

Get notified when new evidence is published on Hereditary ATTR amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents